Researchers at the Bonn University Department of Ophthalmology and US colleagues successfully implanted new cells under the retina
Age-related macular degeneration (AMD) is the most frequent cause of blindness. Scientists at the Department of Ophthalmology at the Bonn University Hospital and from the Neural Stem Cell Institute in New York (USA) have developed a method for using stem cells to replace cells in the eye destroyed by AMD. The implants survived in rabbit eyes for several weeks. Additional research is needed for clinical application. The results are now presented in the journal “Stem Cell Reports”.
About four and a half million people in Germany suffer from age-related macular degeneration (AMD). It is associated with a gradual loss of visual acuity and the ability to read or drive a car can be lost. The center of the field of vision is blurry, as if covered by a veil. This is caused by damage to a cell layer under the retina, known as the retinal pigment epithelium (RPE). It coordinates the metabolism and function of the sensory cells in the eye. Inflammatory processes in this layer are associated with AMD and “metabolic waste” is less efficiently recycled. To date, there is no cure for AMD; treatments can only relieve the symptoms.
Scientists from the Bonn University Department of Ophthalmology, together with researchers in New York (USA), have now tested a new method in rabbits by which the damaged RPE cells in AMD may be replaced. The researchers implanted different RPEs which were obtained, among others, from stem cells from adult human donors. “These cells have now been used for the first time in research for transplantation purposes,” says lead author Dr. Boris V. Stanzel from the Department of Ophthalmology at the University of Bonn. The discovery and characterization of the adult RPE stem cells was performed in the group of Prof. Sally Temple and Dr. Jeffrey Stern from the Neural Stem Cell Institute (NSCI) in New York, USA. Dr. Timothy Blenkinsop at NSCI pioneered methods to grow them to closely resemble true RPE.
Researchers in Bonn developed the implantation techniques
The implantation techniques for the new method were developed by researchers working with Dr. Stanzel from the Department of Ophthalmology at the University of Bonn. They allowed the stem cell derived RPE to grow on small polyester discs, thus yielding a thin cell layer. The researchers implanted this human RPE monolayer in rabbits under the retina. “Our research group developed special instruments to implant the replacement cells can under the retina,” reports Dr. Stanzel. After four days, the researchers used tomographic methods to check whether the replacement cells had integrated into the surrounding cell layers. “The implanted cells were alive,” reports the researcher at the Department of Ophthalmology at the University of Bonn. “That is a clear indication that they have joined with the surrounding cells.” After one week, the implanted cell layer was still stable. Even after four weeks, tissue examinations showed that the transplant was intact.
A new approach for possible treatment of AMD
“The results from the experiments prove that retinal pigment epithelial cells obtained from adult stem cells have the potential to replace cells destroyed by age-related macular degeneration,” summarizes Dr. Stanzel. Moreover, using the newly developed basic method, it will be possible in the future to test which stem cell lines are suitable for transplantation in the eye. “However, clinical application is still far away,” says Dr. Stanzel. More research is needed.
The Latest on: Macular degeneration
[google_news title=”” keyword=”Macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Macular degeneration
- Astellas Pharma gets grant for novel carbocyclic prolinamide derivatives for treating age-related macular degenerationon May 2, 2024 at 6:05 am
Discover Astellas Pharma's patented carbocyclic prolinamide derivatives for treating eye diseases like macular degeneration. Explore the unique compound structure and potential applications in ...
- Can At-Home Vision Tests Detect Active Neovascular AMD?on May 1, 2024 at 5:00 pm
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Three at-home vision-monitoring tools failed to detect worsening neovascular age-related macular degeneration (AMD), a ...
- Macular Disease Foundation warns more than one drink a day can lead to vision losson May 1, 2024 at 8:36 am
is linked to a larger risk of age-related macular degeneration or irreversible vision loss. More than 1.5 million Australians are affected by AMD and the foundation led a systematic review of alcohol ...
- Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degenerationon May 1, 2024 at 4:00 am
Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million ...
- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meetingon May 1, 2024 at 12:00 am
The data continue to reinforce the robust efficacy and safety profile of SYFOVRE ® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “The 11 ...
- macular degenerationon April 30, 2024 at 5:00 pm
Named PRIMA, the device may help those with advanced dry age-related macular degeneration get improvements in their eyesight. The company is in talks to also conduct trials in the United States.
- Texas Company’s Mission to Cure Macular Degeneration Blindnesson April 30, 2024 at 8:14 am
Mesogen Inc. out of The Woodlands, Texas, has developed a transplantable Retinal Pigmented Epithelium (RPE) patch to cure Macular Degeneration Blindness using autologous bone marrow-derived stem cells ...
- Lighthouse Guild Receives Grant from American Macular Degeneration Foundation (AMDF)on April 30, 2024 at 3:30 am
This number is expected to double by 2050, particularly due to age-related vision diseases like macular degeneration. While numerous assistive technology devices are now available, many people with ...
- Local group helps macular degeneration patients cope with vision losson April 26, 2024 at 3:07 am
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- Top 6 Best Eye Supplement for Macular Degeneration in 2024on April 25, 2024 at 1:31 am
Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...
via Bing News